respiratori
tract
infect
major
caus
human
morbid
caus
broad
spectrum
microbi
agent
virus
account
largest
number
respiratori
tract
infect
socal
respiratori
virus
includ
influenza
viru
b
parainfluenza
virus
adenovirus
respiratori
syncyti
viru
rsv
rhinovirus
coronavirus
recent
year
sever
novel
virus
discov
patient
respiratori
infect
use
molecular
biolog
method
novel
virus
includ
human
metapneumoviru
sever
coronavirus
sar
latest
addit
list
human
bocaviru
hbov
describ
alland
et
al
screen
method
unknown
viral
sequenc
patient
sampl
involv
concentr
viral
particl
nucleic
acid
isol
random
amplif
rna
dna
final
sequenc
subsequ
blast
amplifi
product
hbov
close
relat
minut
viru
canin
mvc
bovin
parvoviru
bpv
classifi
genu
bocaviru
within
parvovirida
classic
postul
koch
modifi
river
use
establish
causal
relationship
virus
diseas
howev
hbov
propag
cell
cultur
anim
model
far
therefor
prove
clinic
relev
challeng
applic
postul
koch
river
possibl
first
descript
hbov
dna
detect
swedish
children
lower
respiratori
tract
diseas
three
children
coinfect
virus
two
rsv
one
adenoviru
hbovposit
sampl
neg
respiratori
virus
standard
screen
reason
hbov
may
caus
respiratori
tract
diseas
second
report
hbov
australian
children
adult
hbov
detect
respiratori
sampl
ten
coinfect
rsv
n
hmpv
adenovirus
detect
third
studi
japan
hbov
dna
found
respiratori
specimen
children
lower
respiratori
tract
diseas
sampl
posit
virus
rsv
influenza
viru
b
hmpv
exclud
studi
analysi
doubl
infect
therefor
possibl
two
recent
studi
canada
franc
hbov
dna
detect
nine
respiratori
sampl
respect
canadian
studi
specimen
children
adult
test
specimen
posit
respiratori
virus
exclud
french
studi
examin
sampl
children
five
year
age
three
nine
hbov
dna
posit
children
coinfect
rsv
order
better
understand
epidemiolog
pattern
hbov
infect
analyz
clinic
relev
studi
larger
group
patient
necessari
therefor
retrospect
test
nasopharyng
aspir
patient
univers
children
hospit
germani
presenc
hbov
dna
sampl
test
hbov
infect
consist
store
nasopharyng
aspir
npa
sent
univers
children
hospit
screen
respiratori
virus
januari
septemb
arriv
viral
diagnost
laboratori
sampl
routin
test
presenc
respiratori
viru
antigen
immunofluoresc
assay
respiratori
panel
ifa
kit
chemicon
screen
reagent
kit
detect
antigen
adenovirus
influenza
virus
b
parainfluenza
virus
rsv
npa
show
posit
reaction
screen
reagent
studi
ifa
use
seven
singl
monoclon
antibodi
contain
screen
reagent
remain
npa
materi
store
test
hbov
dna
addit
sampl
small
number
sampl
n
also
avail
retrospect
test
studi
carri
complianc
helsinki
declar
approv
ethic
committe
medic
faculti
univers
dna
extract
npa
sampl
use
high
pure
viral
nucleic
acid
kit
roch
mannheim
germani
accord
instruct
manufactur
elut
volum
amplif
hbov
dna
perform
primer
gagctctgtaagtactattac
ctctgtgttgactgaatacag
describ
alland
use
hotstartaq
dna
polymeras
qiagen
hilden
germani
pcr
reaction
carri
volum
consist
extract
dna
qiagen
hotstar
buffer
dntp
final
concentr
pmol
primer
u
taq
polymeras
cycl
condit
cycl
min
preheat
step
min
amplif
pcr
product
visual
stain
ethidium
bromid
agaros
gel
pcr
reaction
consid
posit
band
expect
size
base
pair
visibl
confirm
sequenc
specif
pcr
product
posit
reaction
sequenc
complet
direct
use
big
dye
termin
chemistri
abi
prism
appli
biosystem
darmstadt
germani
gener
laboratori
procedur
prevent
pcr
contamin
strictli
adher
one
neg
control
extract
amplifi
everi
five
npa
sampl
neg
control
found
neg
hbov
dna
plasmid
contain
pcr
product
clone
vector
invitrogen
use
posit
control
sensit
hbov
assay
approxim
copi
per
reaction
januari
septemb
nasopharyng
aspir
npa
hospit
infant
children
febril
respiratori
tract
diseas
receiv
viral
diagnost
evalu
median
age
patient
year
mean
age
year
rang
day
year
boy
season
distribut
sampl
shown
figur
insuffici
volum
store
materi
sampl
exclud
retrospect
test
hbov
dna
median
age
season
distribut
hospit
significantli
differ
patient
without
suffici
npa
sampl
volum
routin
immunofluoresc
test
antigen
respiratori
virus
posit
diagnosi
obtain
npa
sampl
rsv
n
influenza
viru
n
frequent
found
detail
shown
tabl
coinfect
two
virus
detect
case
use
antigen
assay
npa
test
hbov
dna
sampl
found
posit
pcr
subsequ
sequenc
male
femal
ratio
hbov
posit
infant
children
boy
similar
ratio
popul
test
median
age
year
mean
year
rang
day
year
age
distribut
hbov
posit
patient
rsv
adenoviru
influenza
viru
posit
children
comparison
shown
figur
median
age
significantli
differ
four
infecti
agent
except
comparison
influenza
adenoviru
infect
tabl
infect
rsv
peak
first
six
month
life
median
year
hbov
infect
n
occur
age
year
infect
influenza
viru
evenli
distribut
wider
age
rang
median
year
infect
hbov
found
yearround
though
occur
winter
month
figur
shape
curv
total
number
npa
sampl
receiv
hbov
posit
sampl
appear
almost
parallel
signific
differ
yearli
frequenc
hbov
posit
result
tabl
sampl
avail
hbov
retrospect
found
sampl
two
one
hbov
posit
infant
children
coinfect
respiratori
virus
present
frequent
rsv
n
follow
influenza
n
percentag
distribut
coinfect
agent
among
hbov
posit
sampl
similar
distribut
agent
total
popul
tabl
sequenc
determin
hbov
pcr
product
region
genom
reveal
high
ident
nucleotid
sequenc
obtain
differ
year
comparison
swedish
virus
clinic
data
avail
hbov
posit
npa
patient
suffer
upper
andor
lower
respiratori
tract
diseas
tabl
associ
hbov
infect
distinct
clinic
manifest
appar
retrospect
natur
studi
clinic
data
hbov
neg
sampl
obtain
statist
analysi
aspect
possibl
clinic
diagnos
children
without
coinfect
respiratori
pathogen
compar
pneumonia
found
often
group
children
without
coinfect
tabl
associ
borderlin
signific
p
fisher
exact
test
found
hbov
dna
npa
sampl
obtain
infant
children
respiratori
tract
diseas
year
region
northern
bavaria
germani
highest
frequenc
report
far
knowledg
five
previou
report
hbov
infect
origin
report
sweden
frequenc
report
australia
japan
canada
franc
frequenc
respect
studi
hbov
infect
almost
frequent
found
infect
influenza
viru
second
common
respiratori
infect
consider
frequent
infect
influenza
b
parainfluenza
adenovirus
howev
contrast
pcr
method
use
hbov
detect
respiratori
virus
studi
examin
ifa
compar
detect
frequenc
differ
detect
method
taken
consider
gener
pcr
assay
sensit
antigen
detect
method
therefor
like
true
preval
respiratori
virus
analyz
ifa
actual
higher
report
sever
possibl
explan
higher
frequenc
hbov
infect
observ
studi
compar
previou
report
firstli
differ
may
due
increas
sensit
pcr
assay
previou
studi
well
singl
round
hotstart
pcr
employ
detect
hbov
dna
howev
assay
vari
number
pcr
cycl
perform
cycl
cycl
cycl
present
studi
depend
assay
optim
cycl
may
suffici
detect
weakli
posit
sampl
addit
data
assay
sensit
provid
either
previou
studi
use
plasmid
control
abl
show
assay
regularli
detect
approxim
copi
hbov
dna
per
reaction
order
obtain
inform
amount
hbov
dna
present
npa
secret
realtim
pcr
assay
current
develop
second
potenti
reason
differ
infect
frequenc
studi
may
due
region
tempor
differ
incid
hbov
infect
contrast
previou
report
studi
sampl
one
two
winter
season
npa
studi
collect
four
consecut
year
gener
season
differ
sampl
acquisit
may
account
vari
incid
number
studi
exampl
proport
influenza
parainfluenza
adenoviru
infect
consider
differ
winter
season
data
shown
howev
case
hbov
infect
four
consecut
winter
season
observ
similar
frequenc
approxim
therefor
season
variat
unlik
account
observ
high
frequenc
hbov
infect
studi
popul
far
hbov
detect
sweden
australia
japan
canada
franc
germani
appear
hbov
worldwid
distribut
remain
determin
incid
number
influenc
region
aspect
thirdli
higher
frequenc
observ
studi
may
relat
differ
patient
popul
children
hospit
respiratori
tract
diseas
includ
studi
publish
far
two
studi
addit
examin
adult
outpati
three
studi
well
includ
patient
upper
andor
lower
respiratori
tract
diseas
two
studi
focus
patient
lower
respiratori
tract
diseas
thu
difficult
compar
patient
popul
hbov
studi
agreement
previou
report
sequenc
pcr
product
region
reveal
nucleotid
ident
differ
sampl
also
true
two
hbov
dna
posit
sampl
although
much
sequenc
inform
hbov
requir
data
avail
far
indic
hbov
may
highli
conserv
viru
age
distribut
hbov
infect
found
studi
similar
previou
report
hbov
infect
occur
month
year
age
distribut
compat
protect
infect
matern
antibodi
first
year
life
futur
studi
seropreval
hbov
antibodi
differ
age
group
shed
light
issu
analysi
potenti
associ
hbov
infect
clinic
manifest
limit
retrospect
natur
studi
high
number
doubl
infect
fact
clinic
inform
obtain
hbov
posit
patient
howev
seem
obviou
associ
hbov
infect
distinct
clinic
manifest
instead
broad
spectrum
upper
lower
respiratori
tract
diseas
observ
clinic
diagnos
hbov
dna
posit
patient
without
coinfect
compar
pneumonia
found
frequent
children
without
coinfect
howev
associ
borderlin
signific
p
regard
caution
small
number
pneumonia
caus
hbov
infect
unclear
coinfect
could
result
less
frequent
manifest
diseas
assumpt
first
descript
hbov
viru
might
etiolog
agent
respiratori
tract
diseas
base
fact
hbov
infect
found
significantli
often
sampl
neg
respiratori
virus
howev
coinfect
rate
rang
fom
find
neither
confirm
studi
analyz
coinfect
us
true
number
coinfect
studi
probabl
even
higher
report
antigenbas
method
use
screen
respiratori
virus
hbov
sever
respiratori
pathogen
coronavirus
rhinovirus
enterovirus
human
metapneumoviru
test
basi
consider
number
coinfect
one
might
argu
hbov
aggrav
factor
respiratori
diseas
innoc
bystand
detect
chanc
persist
viru
reactiv
inflammatori
process
thu
uncertain
present
hbov
inde
etiolog
agent
respiratori
tract
diseas
sever
virus
detect
molecular
biolog
method
recent
year
still
search
relev
clinic
diseas
hbov
ad
list
remain
determin
hbov
frequent
found
npa
hospit
children
acut
respiratori
tract
diseas
prove
clinic
relev
hbov
challeng
applic
postul
koch
possibl
high
rate
coinfect
hbov
respiratori
pathogen
associ
hbov
respiratori
tract
diseas
remain
unproven
author
declar
compet
interest
bw
hwk
design
coordin
studi
fn
perform
hbov
dna
test
hwk
kbless
kblath
collect
clinic
data
bw
js
ft
collect
virolog
data
author
particip
data
analysi
bw
fn
draft
manuscript
author
read
approv
final
version
manuscript
prepubl
histori
paper
access
